InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,617.63
(
0.04%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.85
(
-0.02%
)
Bitcoin
62,610.57
(
0.44%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 344

Monday, 09/10/2018 12:48:02 PM

Monday, September 10, 2018 12:48:02 PM

Post# of 438
VBIO Why have Perceptive Advisors accumulated 15% of this company?

The easiest answer is that low-priced biotechs with workable balance sheets and "promising" pipelines have proven to be good risk:reward situations.

Their Ph3 Hepatitis B asset will present top-line data mid/19.

This product has beeen approved in 15 countries including Israel.

Some estimate potential annual revenue for this product at $600mn.

VBIO MC = ~$130mn

Cash runway is only into H1/2019. A $150mn shelf is at the ready.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up